Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Overview

Cinepazide Maleate Injection is widely used in cerebrovascular disease in china. The safety of the cinepazide, especially the blood system, has not been fully evaluated in Chinese population. In order to improve the rational use of cinepazide, the investigators observe its clinical use in the real world in China, evaluate its safety and clinical benefit in a large Chinese population.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2014

Detailed Description

Cinepazide was firstly approved in France in 1974, and the formulations are injection and tablet. Products containing cinepazide have been withdrawn in 1990s by the manufacturers because of lacking of demonstrated efficacy and the risk of agranulocytosis in some European countries, such as France, Spain, Italy. In some Aisa countries, it has not been re-registered in Japan in 2000s, and the injection is still used in China and Korea. In china, Cinepazide Maleate Injection was approved by China Food and Drug Administration(CFDA) in 2002, and widely used in cerebrovascular disease. The safety of the Cinepazide, especially the adverse drug reactions in the blood system, has not benn fully evaluated in Chinese population. In this study, clinical pharmacists in selected hospitals will record the clinical use and the adverse drug reactions/ adverse drug events of this injection. This real world study for Cinepazide Maleate Injection with 18000 patients will be conducted from Sep. 2012 to June. 2014.

Arms, Groups and Cohorts

  • cinepazide
    • Inpatient using the cinepazide in department of neurology

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of adverse drug reaction of cinepazide in department of neurology
    • Time Frame: 1.5 years

Secondary Measures

  • Outcomes of the patients who experienced an adverse drug reaction of cinepazide.
    • Time Frame: 1.5 years
    • Outcomes including cure, improved, null, or death.
  • The predictors of the adverse drug reaction of cinepazide
    • Time Frame: 1.5 years
    • We will analyse whether some factors, such as age, gender, medical history and etc, would be the predictors of the adverse drug reaction of cinepazide.
  • Types of the adverse drug reaction of cinepazide.
    • Time Frame: 1.5 years
    • The types of the adverse drug reaction of cinepazide including Nausea, vomiting, itching and etc.
  • The treatment when patients experienced an adverse drug reaction of cinepazide.
    • Time Frame: 1.5 years
    • Treatments including oxygen, steroids, and etc. According to severity of the adverse drug reactions, we will analyse the features the treatments, such as types and numbers.

Participating in This Clinical Trial

Inclusion Criteria

  • Inpatient using the cinepazide in the department of neurology

Exclusion Criteria

  • none

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University Third Hospital
  • Collaborator
    • Beijing Sihuan Pharmaceutical Co. Ltd.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Suodi ZHAI, Suodi ZHAI, Department of Pharmacy, Peking University Third Hospital – Peking University Third Hospital
  • Overall Contact(s)
    • Suodi ZHAI, BS, +8615611908515, zhaisuodi@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.